Kiora, licenses KIO-301 Korean ophthalmology rights to Chong Kun Dang
KPRX Kiora Pharmaceuticals Inc
$2.59 0.00%
View chart & analysis → - 1Kiora Pharmaceuticals (KPRX) has licensed the Korean development and commercialization rights for ophthalmic KIO-301 to Chong Kun Dang
- 2Kiora will receive an upfront payment of $1 million and is eligible for development and regulatory milestones and royalties on Korean sales
- 3Chong Kun Dang will handle development and commercialization in Korea, expanding the partner network to Korea following the U.S., Europe, Japan, and China
This 3-line summary is compiled from the report below.
Newsfile Corp. +1 View original ↗
오늘의 AI 픽 5종목, 무료로 전부 공개합니다숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다